An investment into neonatal and pediatric patient safety
Rely-V is an innovative IV flow monitoring technology designed for neonatal and pediatric care, offering real-time dosage insights for clinicians
We are working hard to develop the Rely-V technology into a trustworthy platform that can enhance neonatal and pediatric patient care. As we navigate this dynamic market and tackle regulatory challenges, we recognize the invaluable role that partners and investors can play in realizing our vision.
We are actively fund-raising for our seed investment round to enable us to launch the Rely-V research-use device on the market by 2026. Please reach out to us for further information and investment opportunities!
We are actively fund-raising for our seed investment round to enable us to launch the Rely-V research-use device on the market by 2026. Please reach out to us for further information and investment opportunities!
The phase of Rely-V
The Rely-V is currently in the validation phase, we are searching for institutes that would be interested in testing the product and work with us to improve and optimize the opportunities.
Would you like more information about a possible partnership or are you interested as an investor?
Learn more about Sencilia
Sencilia, founded in September 2021, spun out from the University of Groningen with the mission to enhance the safety of IV infusion therapy for vulnerable patients. Our innovative flow sensor technology is being developed in collaboration with renowned partners such as Erasmus Medical Center and the University Medical Center Groningen. We plan to launch our first product, Rely-V, in early 2026, with the vision of becoming the standard of care in IV infusion therapy by 2030.
